Table 3

 Summary of the results of the use of GP IIb/IIIa inhibitors in coronary intervention

Trial Composite primary end-point (<7 days) (%) Composite primary end-point (30 days) (%) Composite primary end-point (6 months) (%) Major bleeding rates (%) Thrombocytopenia (%) Stent rate (%)
EPIC8.3 vs 12.83-150 27vs 353-150 14 vs73-150 5.2 vs 3.43-160 0.6vs 0.6
EPILOG5.2vs 11.73-150 8.4vs 14.73-150 2.0vs 3.13-160 0.4vs 0.415 vs15
CAPTURE11.3 vs 15.93-160 31vs 30.83.8 vs1.93-160 5.6 vs 3.13-160 5.6vs 6.6
RAPPORT3.3vs 9.93-150 5.8 vs11.23-160 11.6 vs 17.83-160 11.6vs 9.53-160 NA0.08vs 0.053-150
IMPACT II6.6vs 9.63-150 9.2 vs11.43-160 NA5.1 vs 4.83.2vs 2.73.6 vs4.5
RESTORE6.9 vs 9.83-160 8.0vs 10.5NA5.3vs 3.71.1 vs0.91.5 vs 2.5
  • For trial names and references see table 2. Figure quoted first is for the active treatment group, the second is for placebo. EPIC: comparison is between bolus plus infusion of abciximab and placebo. EPILOG: comparison is between abciximab/ low-dose heparin regime (70 U/kg) and standard dose heparin (100 U/kg), IMPACT II: comparison is between the low-dose eptifibatide regime (0.5 μg/kg/min) and placebo, <7 day end-point is at 24 h

  • Composite primary end-points: Death, MI, urgent revascularisation (some of the predefined end-points included any revascularisation and have been reanalysed to include only urgent procedures). Thrombocytopaenia: <100 000/mm3, except EPILOG <50 000/mm3.

  • 3-150 p<0.01;

  • 3-160 p<0.05.